Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

CHEK2 Alleles Predispose to Renal Cancer in Poland

CHEK2 Alleles Predispose to Renal Cancer in Poland Letters prove survival for newly diagnosed metastatic non–small cell founder alleles: 1 missense mutation (I157T) and 3 truncating 5,6 lung cancer and prostate cancer. It is likely that this treat- mutations (1100delC, IVS2 + 1G>A, del5395). The I157T allele ment approach would work for other disease sites. Our study was present in 78 participants with renal cancer and 410 generated a hypothesis that suggests that prospective trials control participants (odds ratio [OR], 2.0; 95% CI, 1.6-2.6; evaluating definitive pelvic RT for newly diagnosed meta- P < .001) (unpublished data, 2018). A truncating mutation static cervical cancer are warranted. Although definitive evi- was present in 20 participants and 80 control participants dence is lacking, the choice of pelvic RT remains at the discre- (OR, 2.5; 95% CI, 1.5-4.1; P = .0003) (unpublished data, tion of the treating physician, who considers performance 2018). Unlike the situation for breast cancer, but similar to status, metastatic disease burden, radiation adverse effects and the situation for colon cancer, the risk of cancer associated the patient’s preference. with the missense allele was similar to that of the truncating alleles. In Poland, the number of I157T mutations in patients with renal cancer outnumbered the 1100delC mutations http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

CHEK2 Alleles Predispose to Renal Cancer in Poland

Loading next page...
 
/lp/american-medical-association/chek2-alleles-predispose-to-renal-cancer-in-poland-9pHc07kvMP

References (4)

Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2019.0022
Publisher site
See Article on Publisher Site

Abstract

Letters prove survival for newly diagnosed metastatic non–small cell founder alleles: 1 missense mutation (I157T) and 3 truncating 5,6 lung cancer and prostate cancer. It is likely that this treat- mutations (1100delC, IVS2 + 1G>A, del5395). The I157T allele ment approach would work for other disease sites. Our study was present in 78 participants with renal cancer and 410 generated a hypothesis that suggests that prospective trials control participants (odds ratio [OR], 2.0; 95% CI, 1.6-2.6; evaluating definitive pelvic RT for newly diagnosed meta- P < .001) (unpublished data, 2018). A truncating mutation static cervical cancer are warranted. Although definitive evi- was present in 20 participants and 80 control participants dence is lacking, the choice of pelvic RT remains at the discre- (OR, 2.5; 95% CI, 1.5-4.1; P = .0003) (unpublished data, tion of the treating physician, who considers performance 2018). Unlike the situation for breast cancer, but similar to status, metastatic disease burden, radiation adverse effects and the situation for colon cancer, the risk of cancer associated the patient’s preference. with the missense allele was similar to that of the truncating alleles. In Poland, the number of I157T mutations in patients with renal cancer outnumbered the 1100delC mutations

Journal

JAMA OncologyAmerican Medical Association

Published: Apr 28, 2019

There are no references for this article.